A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard) (Q36102819)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

title

A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard) (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

main subject

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

bevacizumab

1 reference

based on heuristic

inferred from title

oxaliplatin

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

capecitabine

1 reference

based on heuristic

inferred from title

author

Yehuda Patt

series ordinal

7

object named as

Yehuda Z Patt

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

author name string

Herbert Hurwitz

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

Edith P Mitchell

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

Thomas Cartwright

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

Ambrose Kwok

series ordinal

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

Sylvia Hu

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

Edward McKenna

series ordinal

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

language of work or name

English

1 reference

based on heuristic

inferred from title

publication date

23 May 2012

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

published in

Oncologist

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

volume

17

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

issue

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

page(s)

937-946

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

cites work

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Recommended guidelines for the treatment of cancer treatment-induced diarrhea

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

2 October 2017

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

23 September 2018

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

23 September 2018

Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

23 September 2018

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

23 September 2018

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3399650

retrieved

23 September 2018

Identifiers

DOI

10.1634/THEONCOLOGIST.2012-0071

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

PMC publication ID

3399650

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

PubMed publication ID

22622147

1 reference

stated in

Europe PubMed Central

PMC publication ID

3399650

retrieved

12 August 2017

ResearchGate publication ID

225058196

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36102819&oldid=2042170142"